Lind Value II ApS Makes New $1.06 Million Investment in Novo Nordisk A/S (NYSE:NVO)

Lind Value II ApS bought a new stake in shares of Novo Nordisk A/S (NYSE:NVO - Free Report) during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm bought 15,286 shares of the company's stock, valued at approximately $1,061,000. Novo Nordisk A/S makes up approximately 0.5% of Lind Value II ApS's holdings, making the stock its 9th largest holding.

Several other institutional investors also recently bought and sold shares of the stock. GuoLine Advisory Pte Ltd increased its stake in shares of Novo Nordisk A/S by 23.1% in the first quarter. GuoLine Advisory Pte Ltd now owns 426,700 shares of the company's stock worth $29,630,000 after purchasing an additional 80,200 shares during the period. GAMMA Investing LLC boosted its holdings in shares of Novo Nordisk A/S by 7,508.7% in the 1st quarter. GAMMA Investing LLC now owns 657,319 shares of the company's stock worth $45,644,000 after acquiring an additional 648,680 shares in the last quarter. AdvisorNet Financial Inc boosted its holdings in shares of Novo Nordisk A/S by 34.0% in the 1st quarter. AdvisorNet Financial Inc now owns 3,741 shares of the company's stock worth $260,000 after acquiring an additional 950 shares in the last quarter. Webster Bank N. A. boosted its holdings in shares of Novo Nordisk A/S by 708.8% in the 1st quarter. Webster Bank N. A. now owns 39,637 shares of the company's stock worth $2,752,000 after acquiring an additional 34,736 shares in the last quarter. Finally, Sage Capital Advisors llc acquired a new position in shares of Novo Nordisk A/S in the 1st quarter worth approximately $3,210,000. 11.54% of the stock is currently owned by institutional investors.

Novo Nordisk A/S Trading Up 2.8%

Shares of Novo Nordisk A/S stock traded up $1.94 on Friday, hitting $71.40. 11,185,051 shares of the company's stock traded hands, compared to its average volume of 6,787,414. The firm's 50-day moving average price is $65.58 and its two-hundred day moving average price is $81.77. The stock has a market capitalization of $320.41 billion, a PE ratio of 21.70, a price-to-earnings-growth ratio of 0.90 and a beta of 0.65. Novo Nordisk A/S has a one year low of $57.00 and a one year high of $148.15. The company has a debt-to-equity ratio of 0.62, a current ratio of 0.74 and a quick ratio of 0.55.

Novo Nordisk A/S (NYSE:NVO - Get Free Report) last released its quarterly earnings data on Wednesday, May 7th. The company reported $0.92 EPS for the quarter, meeting analysts' consensus estimates of $0.92. Novo Nordisk A/S had a net margin of 34.81% and a return on equity of 84.68%. The business had revenue of $11.87 billion during the quarter. On average, research analysts expect that Novo Nordisk A/S will post 3.84 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several research analysts have recently commented on the company. Stifel Nicolaus downgraded Novo Nordisk A/S from a "buy" rating to a "hold" rating in a report on Monday, March 3rd. BMO Capital Markets reissued a "market perform" rating and issued a $64.00 target price (down from $105.00) on shares of Novo Nordisk A/S in a report on Thursday, April 17th. Guggenheim downgraded Novo Nordisk A/S from a "strong-buy" rating to a "hold" rating in a report on Thursday, April 17th. BNP Paribas assumed coverage on Novo Nordisk A/S in a report on Tuesday, April 15th. They issued an "underperform" rating on the stock. Finally, Hsbc Global Res raised Novo Nordisk A/S to a "strong-buy" rating in a report on Monday, April 28th. Two analysts have rated the stock with a sell rating, five have assigned a hold rating, five have assigned a buy rating and two have given a strong buy rating to the company. Based on data from MarketBeat, Novo Nordisk A/S presently has an average rating of "Moderate Buy" and an average price target of $135.00.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.